SCHEMBL23854549

SCHEMBL23854549

CC(C)(C)CC(=O)Nc1cc(Cl)cc(N2CCOCC2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF18A Q8NI77 2/20 0.52
KCNQ3 O43525 2/20 0.50
KCNQ2 O43526 2/20 0.50
AKT1 P31749 5/20 0.44
PIK3CB P42338 5/20 0.44
PIK3CD O00329 4/20 0.44
PIK3CA P42336 4/20 0.44
PIK3CG P48736 3/20 0.44
MAPT P10636 1/20 0.43
CYP3A4 P08684 3/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
EGFR P00533 2/20 0.42
ERBB3 P21860 1/20 0.42
GAA P10253 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
THRB P10828 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31111409 0.83 ADORA2A (0.59) KIF18AAKT1PIK3CBPIK3CDPIK3CA
SCHEMBL23275363 0.83 ADORA2A (0.59) KIF18AAKT1PIK3CBPIK3CDPIK3CA
SCHEMBL971475 0.77 KCNQ3 (0.68) KCNQ3KCNQ2AKT1MAPTPOLB
SCHEMBL971843 0.77 KCNQ3 (0.59) KCNQ3KCNQ2AKT1PIK3CBPIK3CD
SCHEMBL30796083 0.77 KCNQ3 (0.68) KCNQ3KCNQ2AKT1MAPTPOLB
SCHEMBL30794774 0.77 KCNQ3 (0.59) KCNQ3KCNQ2AKT1PIK3CBPIK3CD
SCHEMBL30824695 0.77 KCNQ2 (0.56) KCNQ3KCNQ2AKT1PIK3CBPIK3CD
SCHEMBL970263 0.77 KCNQ2 (0.56) KCNQ3KCNQ2AKT1PIK3CBPIK3CD
SCHEMBL23275157 0.73 POLB (0.48) KIF18APIK3CBPIK3CDPIK3CAMAPT
SCHEMBL29762362 0.73 POLB (0.48) KIF18APIK3CBPIK3CDPIK3CAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312336-B2 Inhibitors of RAF kinases Pierre Fabre Médicament (FR) 2025-05-27 US disclosed
EP-4048259-A1 INHIBITORS OF RAF KINASES Kinnate Biopharma Inc. (US) 2022-08-31 EP disclosed
US-20210300904-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2021-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300904-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF KIF18A 2665/4885KCNQ3 4288/4885KCNQ2 4021/4885
US-12312336-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF KIF18A 2665/4885KCNQ3 4288/4885KCNQ2 4021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.